These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 16320417)

  • 1. Making real progress against breast cancer. Some of the best cancer news this year has been the success of targeted approaches to treating breast cancer.
    Harv Womens Health Watch; 2005 Oct; 13(2):1-3. PubMed ID: 16320417
    [No Abstract]   [Full Text] [Related]  

  • 2. [Current status and the perspective of treatment strategy for the patients with advanced or recurrent breast cancer].
    Kitagawa D; Toi M
    Nihon Rinsho; 2007 Jun; 65 Suppl 6():396-401. PubMed ID: 17682183
    [No Abstract]   [Full Text] [Related]  

  • 3. [News in the medical treatment of breast cancer].
    Piccart M; Dochy E; Cardoso F
    Bull Cancer; 2003 Jan; 90(1):46-52. PubMed ID: 12609804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Herceptin (trastuzumab)].
    Yamashiro H; Toi M
    Gan To Kagaku Ryoho; 2007 Aug; 34(8):1173-6. PubMed ID: 17687197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiotoxicities of breast cancer treatment.
    Viale PH; Yamamoto DS
    Oncology (Williston Park); 2009 Apr; 23(4 Suppl Nurse Ed):19-24. PubMed ID: 19856594
    [No Abstract]   [Full Text] [Related]  

  • 6. Overview of the impact of conventional systemic therapies on breast cancer.
    Howell A; Wardley AM
    Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S9-S16. PubMed ID: 16113103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Her2-positive breast cancer: herceptin and beyond.
    Dean-Colomb W; Esteva FJ
    Eur J Cancer; 2008 Dec; 44(18):2806-12. PubMed ID: 19022660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lapatinib: new directions in HER2 directed therapy for early stage breast cancer.
    Jo Chien A; Rugo HS
    Cancer Treat Res; 2009; 151():197-215. PubMed ID: 19593514
    [No Abstract]   [Full Text] [Related]  

  • 9. Recent trends of HER-2 examination and a new strategy of trastuzumab therapy for primary and metastatic breast cancer.
    Kurosumi M
    Breast Cancer; 2009; 16(4):283. PubMed ID: 19756922
    [No Abstract]   [Full Text] [Related]  

  • 10. Trastuzumab.
    Perez EA; Palmieri FM; Brock SM
    Cancer Treat Res; 2009; 151():181-96. PubMed ID: 19593513
    [No Abstract]   [Full Text] [Related]  

  • 11. [Trastuzumab. Monoclonal antibody for the treatment of breast cancer].
    Heinzl S
    Med Monatsschr Pharm; 2000 Nov; 23(11):350-2. PubMed ID: 11103587
    [No Abstract]   [Full Text] [Related]  

  • 12. [Quality challenge for immunohistochemistry: example of the ERBB-2 status in breast cancer. Group for Evaluation of Prognostic Factors in Immunohistochemistry in Breast Cancer (GEFPICS)].
    Penault-Llorca F; Jacquemier J; Le Doussal V; Voigt JJ
    Ann Pathol; 1999 Sep; 19(4):280-2. PubMed ID: 10544761
    [No Abstract]   [Full Text] [Related]  

  • 13. Pleomorphic lobular carcinoma of the breast: four long-term responders to trastuzumab--coincidence or hint?
    Mahtani RL; Vogel CL
    J Clin Oncol; 2008 Dec; 26(35):5823-4. PubMed ID: 19001341
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical utility of continuing trastuzumab beyond brain progression in HER-2 positive metastatic breast cancer.
    Metro G; Sperduti I; Russillo M; Milella M; Cognetti F; Fabi A
    Oncologist; 2007 Dec; 12(12):1467-9; author reply 1469-71. PubMed ID: 18165625
    [No Abstract]   [Full Text] [Related]  

  • 15. Beyond HER2 and trastuzumab: heterogeneity, systems biology, and cancer origin research may guide the future for personalized treatment of very early but aggressive breast cancer.
    Roukos DH
    J Clin Oncol; 2010 Jun; 28(17):e279-80; author reply e282-3. PubMed ID: 20406920
    [No Abstract]   [Full Text] [Related]  

  • 16. Trastuzumab in breast cancer.
    Banna GL; Santoro A
    N Engl J Med; 2006 Feb; 354(6):640-4; author reply 640-4. PubMed ID: 16470951
    [No Abstract]   [Full Text] [Related]  

  • 17. HER-2 as a target for breast cancer therapy.
    Ignatiadis M; Desmedt C; Sotiriou C; de Azambuja E; Piccart M
    Clin Cancer Res; 2009 Mar; 15(6):1848-52. PubMed ID: 19289395
    [No Abstract]   [Full Text] [Related]  

  • 18. [Her2/neu receptor: one of the basic factors rendering tailored therapy feasible in breast cancer patients].
    Kulka J
    Orv Hetil; 2005 Apr; 146(17):785-90. PubMed ID: 17918634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Refining therapy for human epidermal growth factor receptor 2-positive breast cancer: T stands for trastuzumab, tumor size, and treatment strategy.
    Burstein HJ; Winer EP
    J Clin Oncol; 2009 Dec; 27(34):5671-3. PubMed ID: 19884535
    [No Abstract]   [Full Text] [Related]  

  • 20. Managing trastuzumab-resistant breast cancer.
    Krop I
    Clin Adv Hematol Oncol; 2009 Feb; 7(2):108-10. PubMed ID: 19367251
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.